Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
about
S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis RestrictionTargeting the Wnt pathways for therapiesAltered Gene Expression in the Schistosome-Transmitting Snail Biomphalaria glabrata following Exposure to Niclosamide, the Active Ingredient in the Widely Used Molluscicide BayluscideNiclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo.Niclosamide is a potential therapeutic for familial adenomatosis polyposis by disrupting Axin-GSK3 interaction.Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model.On the photooxidation of the multifunctional drug niclosamide. A kinetic study in the presence of vitamin B2 and visible light.Crohn's disease-derived monocytes fail to induce Paneth cell defensinsIdentification of compounds that modulate retinol signaling using a cell-based qHTS assay.Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide.Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression.Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposurePreclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family.Antiproliferative and Pro-Apoptotic Effect of Novel Nitro-Substituted Hydroxynaphthanilides on Human Cancer Cell Lines.Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.Existing drugs and their application in drug discovery targeting cancer stem cells.Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.The Simultaneous Inhibitory Effect of Niclosamide on RANKL-Induced Osteoclast Formation and Osteoblast DifferentiationCombined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.Neurocysticercosis: a review on status in India, management, and current therapeutic interventions.Enriched inhibition of cancer and stem-like cancer cells via STAT-3 modulating niclocelles.Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique.Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line.Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth.Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells.Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections.Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia.Combination treatment with fasudil and clioquinol produces synergistic anti-tumor effects in U87 glioblastoma cells by activating apoptosis and autophagy.Tracing and targeting cancer stem cells: New venture for personalized molecular cancer therapy.To Reduce the Global Burden of Human Schistosomiasis, Use 'Old Fashioned' Snail Control.Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1.ROS Modulator Molecules with Therapeutic Potential in Cancers Treatments.Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.Niclosamide as an anti-obesity drug: an experimental study.
P2860
Q26743403-0BB14815-3D87-417E-A25F-D0627BC3E28DQ26821978-4FB349CE-B588-4C8B-A7A5-6AA63A5D6E38Q28550163-421D396F-47E9-4FB6-9186-CF8A0305C611Q30275354-5BF4E96B-F681-4F87-80CE-11CBA2E658AFQ33703068-A00278B5-C712-49EF-A361-8802674BE199Q33761925-61E5BDC4-E8B7-42D4-B41F-84240A95FD69Q35274726-0AA87147-47BB-4959-A3A0-8D4207680AACQ35610614-167DC8C5-A008-478B-9E22-8805C91D642DQ35825462-B04D8DB2-0543-49F5-BE62-FC741C308E47Q35906885-A0F0BC03-EDD9-49CD-8810-C5901A9EDF76Q36083012-E81897E4-B909-49AE-93E6-96CC13924DFBQ36335790-9690A988-F204-45E2-8A30-E4EA42C0ABB3Q36454906-CC3ECF9F-70FA-4E01-92B4-C5C623D2692FQ36962480-C4493936-DB96-4065-BCD0-0F0DA3E4DDF9Q37187561-1160B54A-1087-4CDD-8236-6A05C1645B91Q37209901-736C4F70-8E49-404D-9ACD-40BAF35CD528Q37520468-8A17C4C9-7DAF-4EA1-B328-AF70F6CC52D5Q38543730-4C2B09E2-B950-4A99-9478-09383C4D7C65Q38598774-D4714264-F553-4CCD-A2DD-496C13C81B6EQ38694527-370D1B63-4E57-4004-A488-A02B253ACBACQ38799468-AAFACC65-5B58-4D83-949C-1C95F4D1E60DQ38806842-A6C1963A-9331-4B90-BA14-B78680582713Q38898133-2FB92624-7A08-490A-BD06-9997FA90455AQ38913419-2AD7B628-542C-46CE-9D05-0F725DCE0206Q38958062-B4A8DD97-939E-4FEB-AA79-9A4377C96E7EQ39237865-88D66914-94D4-4806-811D-3C56A090A029Q40064435-3C38566B-F879-4B5C-BC17-98814E82270AQ40075759-4DB39668-F445-4C91-A338-BB6E30A0BA49Q40104743-0EE3B3B9-DA8C-4FD1-A02E-78B34C779E3FQ40226784-6C7FAB98-79EB-48D9-9687-2D20AAA67D0CQ41561381-3F789F7C-5201-4CFE-A981-582C7990F37DQ41847602-4E48C062-AEB0-4687-B7BD-4C6FFF82BBF3Q41916031-1E4C2EB9-96A2-40AD-81AF-2EA39CBF6413Q43258268-4D727F51-ABEF-48EF-B0D4-DB02F3202693Q46226428-E4461E7F-D453-4727-9F8B-EEAF888A1196Q46715656-2890FD7C-E5B0-4E54-A070-1BF95413C1ABQ47232377-D01AA74D-04D6-4D11-B238-E044B3F4918EQ47275485-14EDF3ED-DE38-4F93-A434-7654771FB239Q47705734-A18AA2E5-FB87-45DA-8800-BDB9D25EF6CBQ48151852-9E5491F8-7814-4E1B-ADF9-2655965C62E7
P2860
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
@ast
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
@en
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
@nl
type
label
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
@ast
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
@en
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
@nl
prefLabel
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
@ast
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
@en
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
@nl
P2093
P2860
P1433
P1476
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
@en
P2093
Michael J Roberts
Pui-Kai Li
Rajeev S Samant
Rebecca C Arend
P2860
P356
10.1016/J.CANLET.2014.04.003
P407
P577
2014-04-13T00:00:00Z